Pfizer, Hydra Ink Deal To Develop Novel Ion Channel Antagonists For Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration, valued at $195 million, will focus on transient receptor potential ion channel antagonists for pain.